Dose specific effects of olanzapine in the treatment of alcohol dependence

Rae A. Littlewood, Eric D. Claus, Pamela Arenella, Michael Bogenschutz, Hollis Karoly, Sarah Feldstein Ewing, Angela D. Bryan, Kent E. Hutchison

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Rationale: It is well established that the rewarding effects of alcohol are modulated by the mesolimbic dopaminergic system. Olanzapine, a D2 dopamine antagonist, has been shown to reduce alcohol craving and consumption. Objective: To clarify whether olanzapine has clinical utility in the treatment of alcohol dependence, a 12-week, double-blind, and randomized clinical trial was conducted. Methods: One hundred twenty-nine treatment-seeking alcohol-dependent adults were randomly assigned to 12 weeks of olanzapine (5 vs. 2.5 mg) or placebo. Outcomes examined were average drinks per drinking day (DDD), proportion of drinking days (PDD) to total days in treatment, alcohol craving, and impaired control over alcohol use. Mixed models were used to examine medication effects during the course of treatment on specified outcomes. Results: All of the analyses indicated a main effect for time, such that there were reductions in alcohol use and craving and an increase in control over alcohol use across treatment conditions. Dose-response analyses indicated that, in comparison to placebo, participants in the 5 mg group experienced reduced craving for alcohol and participants in the 2.5 mg group decreased in PDD and increased in their control over alcohol use. Better control over alcohol use remained significant 6 months post-treatment for the 2.5 mg group. Subjective experiences of the medication suggest that 2.5 and 5 mg were equally well tolerated. Conclusions: Results provide some support for the notion that dosage is an important consideration in relation to effectiveness; however, the cost-benefit balance does not support the clinical utility of olanzapine in treating alcohol dependence.

Original languageEnglish (US)
Pages (from-to)1261-1268
Number of pages8
JournalPsychopharmacology
Volume232
Issue number7
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

olanzapine
Alcoholism
Alcohols
Drinking
Therapeutics
Placebos
Alcohol Drinking

Keywords

  • Addiction
  • Alcohol dependence
  • Atypical antipsychotic
  • Dose response
  • Olanzapine
  • Pharmacotherapy
  • Treatment

ASJC Scopus subject areas

  • Pharmacology

Cite this

Littlewood, R. A., Claus, E. D., Arenella, P., Bogenschutz, M., Karoly, H., Feldstein Ewing, S., ... Hutchison, K. E. (2015). Dose specific effects of olanzapine in the treatment of alcohol dependence. Psychopharmacology, 232(7), 1261-1268. https://doi.org/10.1007/s00213-014-3757-1

Dose specific effects of olanzapine in the treatment of alcohol dependence. / Littlewood, Rae A.; Claus, Eric D.; Arenella, Pamela; Bogenschutz, Michael; Karoly, Hollis; Feldstein Ewing, Sarah; Bryan, Angela D.; Hutchison, Kent E.

In: Psychopharmacology, Vol. 232, No. 7, 2015, p. 1261-1268.

Research output: Contribution to journalArticle

Littlewood, RA, Claus, ED, Arenella, P, Bogenschutz, M, Karoly, H, Feldstein Ewing, S, Bryan, AD & Hutchison, KE 2015, 'Dose specific effects of olanzapine in the treatment of alcohol dependence', Psychopharmacology, vol. 232, no. 7, pp. 1261-1268. https://doi.org/10.1007/s00213-014-3757-1
Littlewood, Rae A. ; Claus, Eric D. ; Arenella, Pamela ; Bogenschutz, Michael ; Karoly, Hollis ; Feldstein Ewing, Sarah ; Bryan, Angela D. ; Hutchison, Kent E. / Dose specific effects of olanzapine in the treatment of alcohol dependence. In: Psychopharmacology. 2015 ; Vol. 232, No. 7. pp. 1261-1268.
@article{5b110af2457441d2a23e9d67cec911f2,
title = "Dose specific effects of olanzapine in the treatment of alcohol dependence",
abstract = "Rationale: It is well established that the rewarding effects of alcohol are modulated by the mesolimbic dopaminergic system. Olanzapine, a D2 dopamine antagonist, has been shown to reduce alcohol craving and consumption. Objective: To clarify whether olanzapine has clinical utility in the treatment of alcohol dependence, a 12-week, double-blind, and randomized clinical trial was conducted. Methods: One hundred twenty-nine treatment-seeking alcohol-dependent adults were randomly assigned to 12 weeks of olanzapine (5 vs. 2.5 mg) or placebo. Outcomes examined were average drinks per drinking day (DDD), proportion of drinking days (PDD) to total days in treatment, alcohol craving, and impaired control over alcohol use. Mixed models were used to examine medication effects during the course of treatment on specified outcomes. Results: All of the analyses indicated a main effect for time, such that there were reductions in alcohol use and craving and an increase in control over alcohol use across treatment conditions. Dose-response analyses indicated that, in comparison to placebo, participants in the 5 mg group experienced reduced craving for alcohol and participants in the 2.5 mg group decreased in PDD and increased in their control over alcohol use. Better control over alcohol use remained significant 6 months post-treatment for the 2.5 mg group. Subjective experiences of the medication suggest that 2.5 and 5 mg were equally well tolerated. Conclusions: Results provide some support for the notion that dosage is an important consideration in relation to effectiveness; however, the cost-benefit balance does not support the clinical utility of olanzapine in treating alcohol dependence.",
keywords = "Addiction, Alcohol dependence, Atypical antipsychotic, Dose response, Olanzapine, Pharmacotherapy, Treatment",
author = "Littlewood, {Rae A.} and Claus, {Eric D.} and Pamela Arenella and Michael Bogenschutz and Hollis Karoly and {Feldstein Ewing}, Sarah and Bryan, {Angela D.} and Hutchison, {Kent E.}",
year = "2015",
doi = "10.1007/s00213-014-3757-1",
language = "English (US)",
volume = "232",
pages = "1261--1268",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Dose specific effects of olanzapine in the treatment of alcohol dependence

AU - Littlewood, Rae A.

AU - Claus, Eric D.

AU - Arenella, Pamela

AU - Bogenschutz, Michael

AU - Karoly, Hollis

AU - Feldstein Ewing, Sarah

AU - Bryan, Angela D.

AU - Hutchison, Kent E.

PY - 2015

Y1 - 2015

N2 - Rationale: It is well established that the rewarding effects of alcohol are modulated by the mesolimbic dopaminergic system. Olanzapine, a D2 dopamine antagonist, has been shown to reduce alcohol craving and consumption. Objective: To clarify whether olanzapine has clinical utility in the treatment of alcohol dependence, a 12-week, double-blind, and randomized clinical trial was conducted. Methods: One hundred twenty-nine treatment-seeking alcohol-dependent adults were randomly assigned to 12 weeks of olanzapine (5 vs. 2.5 mg) or placebo. Outcomes examined were average drinks per drinking day (DDD), proportion of drinking days (PDD) to total days in treatment, alcohol craving, and impaired control over alcohol use. Mixed models were used to examine medication effects during the course of treatment on specified outcomes. Results: All of the analyses indicated a main effect for time, such that there were reductions in alcohol use and craving and an increase in control over alcohol use across treatment conditions. Dose-response analyses indicated that, in comparison to placebo, participants in the 5 mg group experienced reduced craving for alcohol and participants in the 2.5 mg group decreased in PDD and increased in their control over alcohol use. Better control over alcohol use remained significant 6 months post-treatment for the 2.5 mg group. Subjective experiences of the medication suggest that 2.5 and 5 mg were equally well tolerated. Conclusions: Results provide some support for the notion that dosage is an important consideration in relation to effectiveness; however, the cost-benefit balance does not support the clinical utility of olanzapine in treating alcohol dependence.

AB - Rationale: It is well established that the rewarding effects of alcohol are modulated by the mesolimbic dopaminergic system. Olanzapine, a D2 dopamine antagonist, has been shown to reduce alcohol craving and consumption. Objective: To clarify whether olanzapine has clinical utility in the treatment of alcohol dependence, a 12-week, double-blind, and randomized clinical trial was conducted. Methods: One hundred twenty-nine treatment-seeking alcohol-dependent adults were randomly assigned to 12 weeks of olanzapine (5 vs. 2.5 mg) or placebo. Outcomes examined were average drinks per drinking day (DDD), proportion of drinking days (PDD) to total days in treatment, alcohol craving, and impaired control over alcohol use. Mixed models were used to examine medication effects during the course of treatment on specified outcomes. Results: All of the analyses indicated a main effect for time, such that there were reductions in alcohol use and craving and an increase in control over alcohol use across treatment conditions. Dose-response analyses indicated that, in comparison to placebo, participants in the 5 mg group experienced reduced craving for alcohol and participants in the 2.5 mg group decreased in PDD and increased in their control over alcohol use. Better control over alcohol use remained significant 6 months post-treatment for the 2.5 mg group. Subjective experiences of the medication suggest that 2.5 and 5 mg were equally well tolerated. Conclusions: Results provide some support for the notion that dosage is an important consideration in relation to effectiveness; however, the cost-benefit balance does not support the clinical utility of olanzapine in treating alcohol dependence.

KW - Addiction

KW - Alcohol dependence

KW - Atypical antipsychotic

KW - Dose response

KW - Olanzapine

KW - Pharmacotherapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84924873767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924873767&partnerID=8YFLogxK

U2 - 10.1007/s00213-014-3757-1

DO - 10.1007/s00213-014-3757-1

M3 - Article

C2 - 25304864

AN - SCOPUS:84924873767

VL - 232

SP - 1261

EP - 1268

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 7

ER -